Interview 29 Jan 2018 Meet the CEO of the Other Big Biotech Acquisition Target in 2017 Christian Schetter’s company, Rigontec, was acquired by MSD last year for nearly half a billion euro. How did he and the company do it, with only one early-stage candidate? There were exactly two notable biotech acquisitions in Europe last year: Actelion and a smaller startup based in Munich called Rigontec, which had an RNA candidate […] January 29, 2018 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 Researchers Take Aim at Pancreatic Cancer with a Modified Flu Virus In an early study at Queen Mary University in London, a modified flu virus has been able to block the growth of pancreatic cancer. For the first time, researchers at Queen Mary University, London, have shown that pancreatic cancer can be targeted using a modified flu virus. During a study, published in Molecular Cancer Therapeutics, […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2018 No Entry! This Protein Could Stop Breast Cancer from Escaping to the Rest of the Body Spanish scientists have found genes that maintain breast cancer cells in a dormant state, which could be manipulated to control the spread of the disease. The time taken for breast cancer to spread varies among patients and not much is known about the mechanisms that control it. Researchers at the Institute for Research in Biomedicine […] January 24, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 New Triple Combination Therapy Boosts Colorectal Cancer Survival Pierre Fabre and Array BioPharma’s combination therapy for colorectal cancer has improved progression-free survival in a Phase III trial. French pharma Pierre Fabre and American biopharma Array BioPharma, has carried out an initial safety lead-in study for a Phase 3 trial evaluating a triple combination therapy for the treatment of metastatic colorectal cancer patients. The therapy was […] January 22, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 PharmaMar Stock Crashes After Failed Ovarian Cancer Study PharmaMar’s cancer drug Zepsyre has failed to prove more effective than chemo to treat ovarian cancer in Phase III, leading to a big hit to its stock. Based in Madrid, PharmaMar develops cancer drugs derived from marine organisms. Unfortunately, one of these compounds, lurbinectedin (Zepsyre), has failed to show better efficacy in treating ovarian cancer than chemotherapy in […] January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2018 French Biotech Closes a €18.5M Series B to Boost Colon Cancer Diagnostics HalioDx hopes that its Immunoscore diagnostics platform can help to provide precision medicine for a number of indications, including colon cancer. HalioDx is an expert in cancer diagnostics, specializing in the analysis of the tumor microenvironment. The company has closed a €18.5M Series B financing round – impressive considering the concerns over reimbursement that investors often have for diagnostic […] January 17, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2018 Here’s Your New Year’s Resolution: Get Your Immune System in Shape If you’re having trouble deciding on a New Year’s resolution, why not train up your immune system? Scientists believe this could help prevent the side effects of chemotherapy. Researchers at Technische Universitaet Dresden believe that by ‘training’ the immune system, cancer patients undergoing chemotherapy could be spared some of the trauma. The study, published in Cell, […] January 17, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 The FDA Gives AstraZeneca’s Breast Cancer Drug the Go-Ahead The UK big pharma company’s Lynparza will be for women with advanced breast cancer that is specifically caused by mutations in the BRCA gene. Global pharma giant AstraZeneca focuses on the development of drugs for cancer, cardiovascular and respiratory diseases. The company, which is working on a number of small molecules and biologics for a […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2018 Here’s Another Reason to Eat Plenty of Fruit and Vegetables Researchers have discovered that bacteria break down fruit and vegetables to produce chemicals that control our genes and could help to prevent cancer and fight infections. British scientists from the Babraham Institute in Cambridge, UK, with colleagues from Brazil and Italy, have discovered a mechanism by which helpful bacteria in the gut can control the […] January 11, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Infographics 10 Jan 2018 Infographic: All You Need to Know About Checkpoint Inhibitors Everything you need to know about what checkpoint inhibitors are and why they have caused a wave of hype for cancer immunotherapies. Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, […] January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Scancell and BioNTech Will Combine Their Expertise to Fight Cancer Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email